Pfizer Gains on Claims Covid-19 Vaccine is Safe for Children Aged 5 to 11 By Investing.com
By Dhirendra Tripathi
Investing.com – Pfizer stock (NYSE:) rose 0.4% on Monday after it said its Covid-19 vaccine was found to be safe for children aged 5 to 11 years.
BioNTech (NASDAQ 🙂 traded 4.4% lower than its German counterpart.
“In participants 5 to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralizing antibody responses,” the company said in a note.
Two doses of 10 micrograms were administered in a three-week interval. The note said the companies plan to submit data to the Food and Drug Administration and other regulators “as soon as possible.”
According to them, companies in the U.S. plan to include data in a short-term submission for emergency authorization. This is to ensure that they have all the necessary safety and efficacy information to apply for FDA approval for this age group.
The companies stated that results for children younger than 5 years old are possible as early as this year.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Trading the financial markets is one of most risky investment options. Please make sure you are fully aware about the costs and risks involved.